6THZ
IRAK4 IN COMPLEX WITH inhibitor
Summary for 6THZ
Entry DOI | 10.2210/pdb6thz/pdb |
Descriptor | Interleukin-1 receptor-associated kinase 4, 7-fluoranyl-~{N}-[1-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrazol-4-yl]-4-(1-methylcyclopropyl)oxy-6-(2-methylpyrimidin-5-yl)pyrido[3,2-d]pyrimidin-2-amine (3 entities in total) |
Functional Keywords | irak4, kinase, inhibitor, cancer, signaling protein |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 2 |
Total formula weight | 70273.13 |
Authors | Xue, Y.,Aagaard, A.,Degorce, S.L. (deposition date: 2019-11-21, release date: 2020-10-28, Last modification date: 2024-05-01) |
Primary citation | Degorce, S.L.,Aagaard, A.,Anjum, R.,Cumming, I.A.,Diene, C.R.,Fallan, C.,Johnson, T.,Leuchowius, K.J.,Orton, A.L.,Pearson, S.,Robb, G.R.,Rosen, A.,Scarfe, G.B.,Scott, J.S.,Smith, J.M.,Steward, O.R.,Terstiege, I.,Tucker, M.J.,Turner, P.,Wilkinson, S.D.,Wrigley, G.L.,Xue, Y. Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors. Bioorg.Med.Chem., 28:115815-115815, 2020 Cited by PubMed: 33091850DOI: 10.1016/j.bmc.2020.115815 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.38 Å) |
Structure validation
Download full validation report